Nextwell Pharmaceutical

Nextwell Pharmaceutical is a clinical-stage biotechnology company headquartered in Shanghai, China, specializing in the development of next-generation small molecule therapeutics. The company leverages its proprietary platform for targeted protein degradation (TPD), including Proteolysis-Targeting Chimeras (PROTACs) and molecular glues, to address unmet medical needs in oncology and immunology. Its lead candidate, NT-165, is a potent and selective IRAK4 degrader designed for the treatment of various autoimmune and inflammatory conditions. Nextwell aims to overcome the limitations of traditional inhibitors by achieving deeper and more durable target inhibition through its innovative degradation technologies. The firm is backed by prominent venture capital investors and focuses on turning historically undruggable targets into viable therapeutic options.